|
|
Line 3: |
Line 3: |
|
| |
|
| {{CMG}}; {{AE}} {{CZ}}, {{SS}} | | {{CMG}}; {{AE}} {{CZ}}, {{SS}} |
|
| |
| ==Overview==
| |
|
| |
| * If the suspected patient complaints with fever,headache,altered level of consciousness, signs of meningeal irritationthe, blood culture or CSF should be obtained urgently,then CT.But DO NOT wait for the results of the [[CT scan]] ''PLUS'' the [[lumbar puncture]]; empiric treatment should be started as soon as possible.
| |
| * Blood cultures should be drawn before starting the [[antibiotic]] therapy, ''PLUS'' then the antibiotic treatment should be changed once the blood culture results are out.
| |
| * Empiric antibiotic treatment should be started within 30 minutes after the patient presentation.
| |
| * In case of high suspicion of pneumococcal meningitis in adult patients, 0.15 mg/kg IV Q6H dexomethasone should be administered for 2 to 4 days.
| |
| ** The first dose of dexomethasone is given along with or 20 minutes prior to starting the antibiotics treatment.<ref name="pmid16394301">van de Beek D, de Gans J, Tunkel AR, Wijdicks EF (2006) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=16394301 Community-acquired bacterial meningitis in adults.] ''N Engl J Med'' 354 (1):44-53. [http://dx.doi.org/10.1056/NEJMra052116 DOI:10.1056/NEJMra052116] PMID: [http://pubmed.gov/16394301 16394301]</ref><ref name="pmid20417414">Edmond K, Clark A, Korczak VS, S''PLUS''erson C, Griffiths UK, Rudan I (2010) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=20417414 Global ''PLUS'' regional risk of disabling sequelae from bacterial meningitis: a systematic review ''PLUS'' meta-analysis.] ''Lancet Infect Dis'' 10 (5):317-28. [http://dx.doi.org/10.1016/S1473-3099(10)70048-7 DOI:10.1016/S1473-3099(10)70048-7] PMID: [http://pubmed.gov/20417414 20417414]</ref><ref name="pmid15494903">Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM et al. (2004) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=15494903 Practice guidelines for the management of bacterial meningitis.] ''Clin Infect Dis'' 39 (9):1267-84. [http://dx.doi.org/10.1086/425368 DOI:10.1086/425368] PMID: [http://pubmed.gov/15494903 15494903]</ref>
| |
|
| |
|
| ==Empiric Therapy== | | ==Empiric Therapy== |
Revision as of 03:51, 20 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2], Sheng Shi, M.D. [3]
Empiric Therapy
Community-Acquired Meningitis
▸ Newborn, Age <1 Week
▸ Newborn, Age 1—4 Weeks
▸ Infant & Children
Infant & Children
|
Preferred Regimen
|
▸ Vancomycin 15 mg/kg IV q6h to achieve serum trough concentrations of 15–20 μg/mL
|
PLUS
|
▸ Cefotaxime 225—300 mg/kg/day IV q6–8h OR ▸Ceftriaxone 80—100 mg/kg/day IV q12–24h
|
|
▸ Adult, Age <50 Years
Adult, Age <50 Years
|
Preferred Regimen
|
▸ Vancomycin 30–60 mg/kg/day IV q8–12h to achieve serum trough concentrations of 15–20 μg/mL
|
PLUS
|
▸ Cefotaxime 8–12 g/day IV q4–6h OR ▸Ceftriaxone 2 g IV q12h
|
† Add Ampicillin 2 g IV q4h (50 mg/kg IV q6h for children) if meningitis caused by Listeria monocytogenes is also suspected.
|
|
▸ Adult, Age >50 Years
▸ Immunocompromised
▸ Recurrent
Healthcare-Associated Meningitis
Adapted from Advances in treatment of bacterial meningitis. Lancet. 2012;380(9854):1693-702.[1]
References
Template:WikiDoc Sources